Open AccessEmergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
Author(s) -
AlKatib Ayad M.,
Gaith Hussein,
Sano Dahlia,
AlKatib Sayf,
Bonnett Michelle,
Kafri Zyad
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3019
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , multiple myeloma , oncology , leukemia , venetoclax
Ibrutinib is approved for chronic lymphocytic leukemia (CLL). However, its role in the treatment of multiple myeloma (MM) is not clear and is under investigation. We report a case of CLL that developed MM while on therapy with ibrutinib indicating that this drug may not be active against MM.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom